{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T15:41:08Z","timestamp":1659368468578},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamainternmed.2022.1952","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:01:30Z","timestamp":1654527690000},"page":"789","source":"Crossref","is-referenced-by-count":0,"title":["Reexamining Medicaid Patient Review and Restriction Programs Amid the Evolving Opioid Epidemic"],"prefix":"10.1001","volume":"182","author":[{"given":"Michael A.","family":"Incze","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, University of Utah, Salt Lake City"},{"name":"Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Taylor","family":"Kelley","sequence":"additional","affiliation":[{"name":"Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"},{"name":"Vulnerable Veteran Innovative Patient-Aligned Care Team (VIP) Initiative; Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Mental Health Law and Policy, College of Behavioral and Community Sciences, University of South Florida, Tampa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"73","key":"ivp220002r4","first-page":"16440","article-title":"Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program.","volume":"83","year":"2018","journal-title":"Fed Regist"},{"issue":"9","key":"ivp220002r6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"ivp220002r7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic.","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"ivp220002r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US.","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ivp220002r10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review.","volume":"168","author":"Fink","year":"2018","journal-title":"Ann Intern Med"},{"key":"ivp220002r1","volume-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2021"},{"key":"ivp220002r2","unstructured":"Gertner? AK. Lock-in programs may be doing more harm than good\u2014and Congress is considering expanding them. Health Affairs. Accessed March 11, 2022. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20180629.14455\/full\/"},{"key":"ivp220002r3","unstructured":"American Society of Addiction Medicine. Public policy statement on patient review and restriction (PRR) programs. Accessed May 3, 2022. https:\/\/www.asam.org\/advocacy\/public-policy-statements\/details\/public-policy-statements\/2021\/08\/09\/patient-review-and-restriction-(prr)-programs"},{"key":"ivp220002r5","unstructured":"Medicaid and CHIP Payment and Access Commission. Pharmacy and provider lock-in programs in Medicaid fee for service. Accessed December 5, 2021. https:\/\/www.macpac.gov\/publication\/pharmacy-and-provider-lock-in-programs-in-medicaid-fee-for-service\/"},{"key":"ivp220002r9","unstructured":"Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act, Pub L No. 115-271 (2018). Accessed May 3, 2022. https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2792896\/jamainternal_incze_2022_vp_220002_1658163796.61596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T15:13:18Z","timestamp":1659366798000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2792896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.1952","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}